NTRK Fusion in Lung Cancer and the Role of TRK Inhibitors

Review the rationale for screening patients with lung cancer for NTRK fusions and integrating TRK inhibitors into their treatment.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Overview and Rationale for Targeting TRK in NSCLC
  • NTRK Fusion Frequency and Diagnosis in NSCLC
  • Clinical Data and Current Indications for TRK Inhibitors in Multiple Cancer Settings
  • Investigation of Additional Targets of TRK Inhibitors
  • Ongoing Clinical Trials


Date / Time
Event Details


Todd Bauer, MD

Associate Director, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to screen patients with lung cancer for NTRK fusions and integrate TRK inhibitors into treatment of their patients with lung cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the biology of and rationale for targeting NSCLC harboring NTRK fusions
  • Identify patients with NSCLC who should be tested for NTRK fusions with established and emerging biomarker assays
  • Describe the research data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC
  • Formulate strategies for using TRK inhibitors in the management of patients with NSCLC
  • Develop treatment strategies for patients with NSCLC who develop acquired resistance to first-generation TRK inhibitor therapy
  • Refer patients with NSCLC to ongoing late-phase clinical trials of TRK inhibitors


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.